Dong-A ST’s subsidiary, Dong-A Chammed, is set to participate in the 2026 Spring Symposium of the Korean Society for Laboratory Medicine. The event will take place on April 23-24 at the Swiss Grand Hotel in Hongje-dong, Seodaemun-gu, Seoul.
Industry sources reported on April 23 that this symposium, themed Laboratory Intelligence: Data Meets Diagnostics, will serve as a platform for domestic and international experts in laboratory medicine to exchange cutting-edge research trends and technological insights.
At the symposium, Dong-A Chammed will showcase an array of innovative products. These include the LIAISON XL automated fluorescent immunoassay system, the GNT-9 blood collection preparation automation system, the Indiko Plus fully automated biochemical analyzer, the HubCentra 84 blood culture equipment, and ED WIPES disinfectant wipes for infection prevention.
The company will also unveil its plans to enter the in vitro diagnostic blood coagulation testing market. Dong-A Chammed recently inked a distribution agreement with STAGO, a global leader in blood coagulation testing equipment and reagents. The firm is now preparing to navigate the domestic regulatory approval process for STAGO’s products.
By expanding into blood coagulation testing, Dong-A Chammed aims to broaden its portfolio beyond its current offerings of blood collection tubes, needles, automated tube labeling equipment, biochemical analyzers, fluorescent immunoassay devices, and blood culture equipment. This strategic move is designed to establish a comprehensive IVD solution.
A spokesperson for Dong-A Chammed stated that the entry into the blood coagulation testing field will allows them to expand the existing In Vitro Diagnostic (IVD) portfolio and develop an integrated IVD solution covering all stages from pre-testing to diagnosis. Following the necessary regulatory approvals, it plans to introduce these products sequentially and continue to strengthen the competitive edge in the market.
Dong-A Chammed, a subsidiary of Dong-A ST, is a specialized medical healthcare company. It operates through three main divisions: ENT Medical Devices (EMD), which produces and exports otolaryngology equipment and medical imaging devices; IVD, which handles blood collection consumables and in vitro diagnostic medical devices; and Healthcare-Associated Infection (HAI), which focuses on space disinfection systems, endoscope disinfectors, specialized disinfectants, and disinfectant wipes.